A Safety Study of XL019 in Adults With Myelofibrosis
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of XL019 in adults with
myelofibrosis. XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. JAK2
is activated by cytokine and growth factor receptors and phosphorylates members of the STAT
family of inducible transcription factors. Activation of the JAK/STAT pathway promotes cell
growth and survival, and is a common feature of human tumors. JAK2 is activated by mutation
in the majority of patients with myelofibrosis, polycythemia vera and essential
thrombocytosis and appears to drive the inappropriate growth of blood cells in these
conditions.